Examining visual field defects in the paediatric population exposed to vigabatrin

Documenta Ophthalmologica

Volumn 107, Issue 3, 2003, Pages 281-287

  Spencer, Emma L ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

Children; Field specific VEP; Vigabatrin; Visual loss

Indexed keywords

ANTICONVULSIVE AGENT; VIGABATRIN;

ADOLESCENT; AMPLITUDE MODULATION; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EXPOSURE; ELECTRODE; ELECTRORETINOGRAPHY; EVOKED VISUAL RESPONSE; HUMAN; INFANTILE SPASM; OCCIPITAL CORTEX; PERIMETRY; POPULATION RESEARCH; PREVALENCE; RELIABILITY; SENSITIVITY AND SPECIFICITY; VISUAL FIELD; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT; VISUAL STIMULATION;

ADOLESCENT; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; ELECTRORETINOGRAPHY; EVOKED POTENTIALS, VISUAL; HUMANS; PERIMETRY; SENSITIVITY AND SPECIFICITY; VIGABATRIN; VISION DISORDERS; VISUAL FIELDS;

EID: 0346252600     PISSN: 00124486     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:DOOP.0000005337.39947.83     Document Type: Article

References (28)

1. Perucca E. Efficacy and tolerability with long-term administration of vigabatrin. Br J Clin Pract 1988; 42 (Suppl. 61): 3.
2. Appleton RE. Vigabatrin in the management of generalized seizures in children. Seizure 1995; 4: 45-8.
3. Cubells JF, Blanchard JS, Smith DM, Makman MH. In vivo action of enzyme-activated irreversible inhibitors of glutamic acid decarboxylase and γ-aminobutyric acid transaminase in retina vs. brain. J Pharmacol Exp Ther 1986; 238(2): 508-14.
4. Eke T, Talbot J, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. Br Med J 1997; 314: 180-1.
5. Harding GFA. Severe persistent visual field constriction associated with vigabatrin. Four possible mechanisms exist. Br Med J 1997; 314: 1694.
6. Krauss GL, Johnson MA, Miller NR. Vigabatrin-associated retinal cone system dysfunction. Electroretinogram Ophthalmol Find Neurol 1998; 50: 814-9.
7. Arndt CF, Derambure P, Defoort-Dhellemmes S, Hache JC. Outer retinal dysfunction in patients treated with vigabatrin. Neurology 1999; 52: 1201-5.
8. Daneshvar H, Racette L, Coupland SG, Kertes PJ, Guberman A, Zakon D. Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophthalmology 1999; 106: 1792-8.
9. Kalvianien R, Nousiainen I, Mantyjarvi M, et al. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field constriction. Neurology 1999; 53: 922-6.
10. Lawden MC, Eke T, Degg C, Harding GFA, Wild JM. Visual field defects associated with vigabatrin therapy. J Neurol, Neurosurg Psychiatry 1999; 67: 716-22.
11. Wild JM, Martinez C, Reinshagen G, Harding GFA. Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 1999; 40: 1784-94.
12. Miller NR, Johnson MA, Paul SR, et al. Visual dysfunction in patients receiving vigabatrin. Clinical and electrophysiological findings. Neurology 1999; 53: 2082-7.
13. Paul SR, Krauss GL, Miller NR, Medura MT, Miller TA, Johnson MA. Visual function is stable in patients who continue long-term vigabatrin therapy: Implications for clinical decision making. Epilepsia 2001; 42: 525-30.
14. Malmgren K, Ben-Menachem E, Frisén L. Vigabatrin visual toxicity: Evolution and dose dependence. Epilepsia 2001; 42: 609-15.
15. Hardus P, Verduin WM, Englesman M, et al. Visual field loss associated with vigabatrin: Quantification and relation to dosage. Epilepsia 2001; 42: 262-7.
16. Hammond EJ, Rangel RJ, Wilder BJ. Evoked potential monitoring of vigabatrin patients. Br J Clin Pract 1989; 61: 16-23.
17. Cosi V, Callieco R, Galimberti CA, et al. Effects of vigabatrin on evoked potentials in epileptic patients. Br J Clin Pharmacol 1989; 27: 61-8S.
18. Liegeois-Chauvel C, Marquis P, Gisselbrecht D, Pantieri R, Beaumont D, Chauvel P. Effects of long-term vigabatrin on somatosensory-evoked potentials in epileptic patients. Epilepsia 1989; 30: S23-5.
19. Harding GFA, Jones LA, Tipper VJ, Betts TA, Mumford JP. Electroretinogram, pattern electroretinogram and visual evoked potential assessment in patients receiving vigabatrin. Epilepsia 1995; 36: S108.
20. Mauguière F, Chauvel P, Dewailly J, Dousse N. No effect of long-term vigabatrin treatment on CNS conduction in epileptic patients: Results of a multicenter study of somatosensory and visual evoked potentials. Epilepsia 1995; 36: 29.
21. Harding GFA, Robertson KA, Edson AS, Barnes P, Wild JM. Visual electrophysiological effect of a GABA transaminase blocker. Doc Ophthalmol. 1999; 97: 179-88.
22. Harding GFA, Wild JM, Robertson KA, Rietbrock S, Martinez C. Separating the retinal electrophysiologic effects of vigabatrin - Treatment versus field loss. Neurology 2000; 55(3): 347-52.
23. Harding GFA, Wild JM, Robertson K, et al. EOGs, ERGs, VEPs and multifocal ERGs in epileptic patients showing visual field constriction. Epilepsia 2000; 41(11): 1420-31.
24. Chiron C, Dulac O, Beaumont D, Palacios L, Pajot N, Mumford J. Therapeutic trial of vigabatrin in refactory infantile spasms. J Child Neurol 1991; 6: 2S52-9.
25. Harding GFA, Robertson K, Holliday I, Jones L. Field-specific visual evoked potentials for assessment of peripheral field defect in a paediatric population. J Physiol 1999; 518P: 171P.
26. Harding GFA, Robertson KA, Holliday I. Field specific visual evoked potentials for assessment of peripheral field fect in a paediatric population. In: Ambler Z, Nevpímalová S, Kadaòka Z, Rossini PM, eds. Clinical Neurophysiology at the Beginning of the 21st Century. Supplements to Clin Neurophysiol 2000; 53: 323-30.
27. Harding GFA, Spencer EL, Wild JM, Conway M, Bohn RL. Field-specific visual evoked potentials: Identifying field defects in vigabatrin-treated children. Neurology 2002; 58: 1261-5.
28. Marmor MF, Zrenner E. Standard for clinical electroretinography. Doc Ophthalmol 1998; 97: 143-56.